Yahoo Web Search

Search results

    • Argenx soars on CIDP shot approval

      Investing.com via Yahoo Singapore Finance· 6 days ago

      Argenx expects annual net revenue per patient per year of around $450,000 for U.S. CIDP patient. UBS keeps a ‘neutral’ rating for now, but lifts its 12-month target price to $430 from $410.

    • 3 Great Mutual Fund Picks for Your Retirement

      3 Great Mutual Fund Picks for Your Retirement

      Zacks via Yahoo Singapore Finance· 6 days ago

      With yearly returns of 17.95% over the last five years, NVLIX is an effectively diversified fund with a long reputation of solidly positive performance....